Alkermes plc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Alkermes reappointed Blair C. Jackson as President and CEO under a new employment agreement effective August 1, 2026, replacing the prior agreement. The agreement specifies severance of 1.5× (base salary + average incentive compensation) payable over 18 months if terminated without cause or upon good reason; 2× multiplier applies within 24 months post-change-of-control. Jackson also received a performance-vesting stock option grant (specific grant amount, exercise price, and performance metrics not disclosed in this exhibit). No specific base salary, bonus target, or option grant details are stated in the filing text.
Why this rating
CEO contract renewal is routine governance. Severance terms are standard for a $4.7B pharma company. No new equity, financial commitment, or strategic change disclosed; no quantified grant size or salary disclosed here.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.